Skip to NavigationSkip to content


GSK acquires oncology firm Tesaro for $5.1 billion

British multinational GlaxoSmithKline (GSK) have acquired US oncology firm Tesaro for $5.1 billion (£4 billion).

Tesaro, a Massachusetts-based clinical stage biopharmaceutical company, won approval for ovarian cancer drug Zejula in March 2017. Zejula, an oral poly ADP ribose polymerase (PARP) inhibitor, is currently approved in the US and Europe for adults with recurrent ovarian cancer.

GSK to acquire oncology biotech Tesaro for $5.1 billion

GlaxoSmithKline is set to acquire US-based oncology biotech Tesaro after both companies signed a definitive agreement with an aggregate cash valuation of $5.1 billion.

A key element of the deal is that GSK will pick up Tesaro’s oral poly ADP ribose polymerase (PARP) inhibitor Zejula (niraparib), which has already secured US and EU approval in the treatment of recurrent ovarian cancer in patients who are in response to platinum-based chemotherapy, regardless of BRCA mutation or biomarker status.

New PARP inhibitor hits UK market, offering distinct advantage

Tesaro’s Zejula has been launched in the UK but availability on the NHS has still not been decided. The PARP inhibitor will be made available through private health insurance based on strong data revealed in recent clinical trials.

The data showed that the drug was able to boost progression-free survival in both patients with the BRCA mutation (BRCA1 or BRCA2) and also in patients who did not display the gene mutation.

Tesaro secures EU approval in specific ovarian cancer population

The European Commission has granted Tesaro’s Zejula (niraparib) marketing approval in Europe, it has emerged.  Zejula is a poly (ADP-ribose) polymerase (PARP)1/2 inhibitor and is indicated as a monotherapy for maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. The drug does not require BRCA mutation or other biomarker testing.

Tesaro's ovarian cancer drug success threatens market rivals

Phase III results from Tesaro’s niraparib PARP inhibitor could spell trouble for rivals Roche and AstraZeneca as its showed sizeable benefit in treating women with recurrent ovarian cancer with success in 70% of patients.

Tesaro's niraparib hits primary goal in late-stage trials for ovarian cancer trial; shares jump

Shares in Tesaro (Nasdaq: TSRO) jumped to more than double after the company reported late-stage trials for its drug to treat ovarian cancer met its primary endpoint of progression-free survival (PFS).

The company said a Phase III study of niraparib showed the trial drug significantly prolonged PFS compared to control among patients who are germline BRCA mutation carriers.

Tesaro said it is planning US and EU marketing submissions for the oral PARP inhibitor.

Tesaro shares rise as J&J buys rights to prostate cancer drug for $85 million

Shares in oncology-focussed Tesaro Inc (Nasdaq: TSRO) jumped Wednesday after the company said pharma major Johnson & Johnson (NYSE: JNJ) will pay $85 million for rights to develop and sell its trial-drug to treat prostate cancer.

Under the terms of the deal J&J will invest $50 million in Tesaro’s stock, paying $44.24 a share. In addition, the company will pay $35 million in cash up front for rights to the cancer drug, niraparib, Tesaro said in a statement.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches